We are driven by respect for the bold entrepreneurs who wake up every morning with the same goal as Magnetic – to improve patients’ lives. With more than 25 years of multifaceted experience at large pharmaceutical and diagnostic companies, start-ups, and as investors, we respect the company building process and are here for our founders, every step of the way.

We understand the complex world of healthcare.

With regulatory and market dynamics unique to the sector, we know how to navigate these complexities and understand the entire lifecycle of healthcare – from discovery, to regulatory, through commercialization. During our decades in the industry, we’ve sat in FDA meetings, negotiated business development deals, and have launched and scaled some of the most ground-breaking technologies and companies in the sector.

Portfolio

View Our Portfolio ›
Using active-graph machine learning (ML) combined with single-cell analysis to advance therapeutic candidates for diseases with no or few good medicines.
Unlocking the potential of microfluidics and machine learning to discover modulators of biomolecular condensates in human disease.
Using cellular barcoding technology to transform clinical decision making in oncology patients.
Changing the way complex medicines are made and distributed through technology innovation
Improving healthcare for minority patients through technology-based patient engagement solutions
Using AI to rapidly accelerate drug discovery and development for rare genetic diseases

In the News

View All ›
Endpoints News
08.15.22

Resilience collaborates with the Mayo Clinic to manufacture rare and complex disease drugs

Endpoints News
06.09.22

Exclusive: Pfizer vet grabs $25M seed round to ‘integrate’ machine learning, genomics tech in drug R&D (Relation Therapeutics)

Endpoints News
06.08.22

Resilience nets another deal, this time with billionaire’s cancer research center

Bloomberg
06.06.22

Resilience Announces $625 Million Series D Financing to Expand Network, Bring Innovative Technologies to Biomanufacturing

Endpoints News
06.02.22

The target is the system: Condensates biotech aspires to ‘rewrite the rulebook’ on drug discovery (Transition Bio)